MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept of change(s) to the agreed paediatric investigation plan

MHRA-101162-PIP01-23-M01

Scope of the Application

Active Substance(s)

LETERMOVIR

Condition(s)

Prevention of cytomegalovirus infection

Pharmaceutical Form(s)

Film-coated tablets; Granules; Concentrate for solution for infusion

Route(s) of Administration

ORAL USE; INTRAVENOUS USE

Name / Corporate name of the PIP applicant

Merck Sharp & Dohme (UK) Ltd

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Merck Sharp & Dohme (UK) Ltd submitted to the licensing authority on 30/08/2023 18:39 BST an application for a Modification

The procedure started on 04/12/2023 09:11 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101162-PIP01-23-M01

Of 13/02/2024 17:04 GMT

On the adopted decision for LETERMOVIR (MHRA-101162-PIP01-23-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for LETERMOVIR, Film-coated tablets; Granules; Concentrate for solution for infusion , ORAL USE; INTRAVENOUS USE .

This decision is addressed to Merck Sharp & Dohme (UK) Ltd , 120 Moorgate, London, UNITED KINGDOM, EC2M 6UR

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Prevention of cytomegalovirus infection

2.2 Indication(s) targeted by the PIP:

Prevention of CMV viraemia and / or disease in at-risk patients having undergone an allogeneic haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT)

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Film-coated tablets Granules Concentrate for solution for infusion

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Deleted during procedure EMEA-001631-PIP01-14-M02. Study 2 Development of granules. Study 3 Deleted during procedure MHRA-101162-PIP01-23-M01.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	2	Study 4 Open-label, single-arm trial to evaluate pharmacokinetics, safety and acceptability/palatability of letermovir in children from birth to less than 18 years of age who are at-risk of developing CMV infection and/or disease following allogeneic haematopoietic stem cell transplantation. Study 5 Open-label, randomised trial in healthy adult volunteers to determine the bioavailability of the letermovir paediatric formulation(s) relative to the adult film-coated tablet.
Extrapolation, Modeling & Simulation Studies	2	Study 6 Modelling and Simulation study to support dose finding and the extrapolation of efficacy of letermovir from adult haematopoietic stem cell transplant (HSCT) recipients to children from birth to less than 18 years of age who are at-risk of developing CMV infection and/or disease following HSCT. Study 7 Extrapolation study to support the use of letermovir in children from birth to less than 18 years of age who are at-risk of

		developing CMV infection and/ or disease following solid organ transplantation.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/08/2023
Deferral of one or more studies contained in the paediatric investigation plan:	Yes